ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN

Aim. To study efficacy and tolerability of antihypertensive therapy with enalapril (Berlipril®, Berlin-Chemie AG/Menarini Group) and diltiazem (Altiazem® PP, Berlin-Chemie AG/Menarini Group) in postmenopausal women with arterial hypertension (HT) and climacteric disorders.Material and methods. 60 po...

Full description

Bibliographic Details
Main Authors: A. A. Kirichenko, Z. M. Tankieva
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/1138
id doaj-5a3b4764f5b54f5585d202cf973d67ea
record_format Article
spelling doaj-5a3b4764f5b54f5585d202cf973d67ea2021-09-03T13:15:24ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-0144545810.20996/1819-6446-2008-4-4-54-581137ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMENA. A. Kirichenko0Z. M. Tankieva1Russian Medical Academy of Postgraduate Educational, Barrikadnaya ul. 2/1, 123995 MoscowRussian Medical Academy of Postgraduate Educational, Barrikadnaya ul. 2/1, 123995 MoscowAim. To study efficacy and tolerability of antihypertensive therapy with enalapril (Berlipril®, Berlin-Chemie AG/Menarini Group) and diltiazem (Altiazem® PP, Berlin-Chemie AG/Menarini Group) in postmenopausal women with arterial hypertension (HT) and climacteric disorders.Material and methods. 60 postmenopausal women (aged 56,8±3,9 y.o.) with HT of 1-3 degrees were included into the study. They were split in two groups. Patients of the first group (30 people) received enalapril (Berlipril®) 20 mg/daily, patients of the second group (30 people) – diltiazem (Altiazem® PP) 180-360 mg/daily. Observation period was 6 months. Ambulatory blood pressure monitoring (ABPM) was performed before treatment and after 3 weeks, 1, 3 and 6 months of therapy. Climacteric syndrome severity and urodynamic disorders was estimated as well as psychic status according to score of depression and anxiety.Results. Office and ambulance blood pressure decreased after 6 months of therapy in all patients of both groups. A number of complaints on headache and giddiness reduced significantly. Severity of climacteric syndrome also decreased. Enalapril (Berlipril®) monotherapy and especially combined therapy with hydrochlorothiazide led to aggravation of urodinamic disorders. On the contrary both monotherapy with diltiazem (Altiazem® PP) or its combination with hydrochlorothiazide had positive effect on urodinamics. Both therapies reduced depression and anxiety levels significantly.Conclusion. All spectrum of pharmacology effects should be taken into account during antihypertensive therapy of patients with climacteric disorders.https://www.rpcardio.com/jour/article/view/1138arterial hypertensionpostmenopauseclimacteric syndromeurodinamic disorders
collection DOAJ
language English
format Article
sources DOAJ
author A. A. Kirichenko
Z. M. Tankieva
spellingShingle A. A. Kirichenko
Z. M. Tankieva
ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN
Racionalʹnaâ Farmakoterapiâ v Kardiologii
arterial hypertension
postmenopause
climacteric syndrome
urodinamic disorders
author_facet A. A. Kirichenko
Z. M. Tankieva
author_sort A. A. Kirichenko
title ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN
title_short ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN
title_full ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN
title_fullStr ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN
title_full_unstemmed ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN
title_sort antihypertensive therapy and climacteric disorders in postmenopausal women
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2016-01-01
description Aim. To study efficacy and tolerability of antihypertensive therapy with enalapril (Berlipril®, Berlin-Chemie AG/Menarini Group) and diltiazem (Altiazem® PP, Berlin-Chemie AG/Menarini Group) in postmenopausal women with arterial hypertension (HT) and climacteric disorders.Material and methods. 60 postmenopausal women (aged 56,8±3,9 y.o.) with HT of 1-3 degrees were included into the study. They were split in two groups. Patients of the first group (30 people) received enalapril (Berlipril®) 20 mg/daily, patients of the second group (30 people) – diltiazem (Altiazem® PP) 180-360 mg/daily. Observation period was 6 months. Ambulatory blood pressure monitoring (ABPM) was performed before treatment and after 3 weeks, 1, 3 and 6 months of therapy. Climacteric syndrome severity and urodynamic disorders was estimated as well as psychic status according to score of depression and anxiety.Results. Office and ambulance blood pressure decreased after 6 months of therapy in all patients of both groups. A number of complaints on headache and giddiness reduced significantly. Severity of climacteric syndrome also decreased. Enalapril (Berlipril®) monotherapy and especially combined therapy with hydrochlorothiazide led to aggravation of urodinamic disorders. On the contrary both monotherapy with diltiazem (Altiazem® PP) or its combination with hydrochlorothiazide had positive effect on urodinamics. Both therapies reduced depression and anxiety levels significantly.Conclusion. All spectrum of pharmacology effects should be taken into account during antihypertensive therapy of patients with climacteric disorders.
topic arterial hypertension
postmenopause
climacteric syndrome
urodinamic disorders
url https://www.rpcardio.com/jour/article/view/1138
work_keys_str_mv AT aakirichenko antihypertensivetherapyandclimactericdisordersinpostmenopausalwomen
AT zmtankieva antihypertensivetherapyandclimactericdisordersinpostmenopausalwomen
_version_ 1717816640815497216